Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Feb. 8, 2024

Objective Increasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified validated single-center retrospective cohort. Methods The clinical data 192 ICI-treated retrospectively analyzed. pretreatment levels CRP, PS, LDH, ALB dNLR were scored respectively then their scores added up to form index. correlation index with progression-free survival (PFS) or overall (OS) analyzed by Kaplan–Meier model. multivariate analysis used identify whether an independent predictor. Results A total 88 104 included low high group respectively. High significantly correlated worse PFS OS (both p<0.001). revealed unfavorable factor affecting (hazard (HR)=1.821; 95%confidence interval (CI)=1.291-2.568) (HR=2.058, 95%CI=1.431-2.959). had lower disease control rate than (p=0.024), while no significant difference found for objective response (p=0.172). subgroup on features (pathological type, therapy strategy, TNM stage age) confirmed value index, except ICI monotherapy age ranging from 18 65 years old. Finally, nomogram constructed age, gender, smoking status, which could predict well 1-, 2- 3-year patients. Conclusion has great be utilized non-invasive, inexpensive reliable ICI-based

Language: Английский

---

Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or Immunotherapy in Spain: A Single-Center, Real-World, Exploratory Study

Cancers, Journal Year: 2024, Volume and Issue: 16(11), P. 2068 - 2068

Published: May 30, 2024

The objective of this observational, single-center, retrospective study conducted in a Spanish tertiary hospital was to describe the real-world (RW) healthcare resource utilization (HCRU) among patients with advanced non-small-cell lung cancer (aNSCLC) who received chemotherapy (CT) or immunotherapy (IT) as first and second lines treatment. A total 173 diagnosed aNSCLC treated between January 2016 August 2020 were included. standardized average costs per patient/year EUR 40,973.2 22,502.4 for first-line CT IT 140,601.3 20,175.9 second-line IT, respectively. annual patient associated adverse-event (AE) onset 29,939.7 460.7 35,906.4 3206.1 disease management 33,178.0 22,448.4 127,134.2 19,663.9 In conclusion, use showed lower cost patient, which HCRU both AE management, compared CT. However, these results should be further confirmed context currently implemented treatment schemes, including combination single dual IT.

Language: Английский

---

Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab

British Journal of Nursing, Journal Year: 2024, Volume and Issue: 33(Sup17), P. S1 - S13

Published: Sept. 1, 2024

Language: Английский

---

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies

Biomolecules, Journal Year: 2024, Volume and Issue: 14(12), P. 1581 - 1581

Published: Dec. 11, 2024

Immunotherapy has shown significant improvement in the survival of patients with hepatocellular carcinoma (HCC) compared to TKIs as first-line treatment. Unfortunately, approximately 30% HCC exhibits intrinsic resistance ICIs, making new therapeutic combinations urgently needed. The dysregulation Notch signaling pathway observed can affect immune cell response, reducing efficacy cancer immunotherapy. Here, we provide an overview how regulates responses and present rationale for combining inhibition ICIs improve Moreover, propose using exosomes non-invasive tools assess activation hepatic cells, enabling accurate stratification who benefit from combined strategies.

Language: Английский

---

The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer

Cancer Treatment and Research Communications, Journal Year: 2024, Volume and Issue: 40, P. 100833 - 100833

Published: Jan. 1, 2024

The data on immune checkpoint inhibitors (ICI) use in lung cancer individuals generally underrepresented clinical trials are limited. We aimed to examine the ICI access, safety, and outcome these populations using real-world data. Patients with newly started ICIs from 2018 2021 were included. Patient factors (age, sex, race, insurance, Charlson comorbidity index (CCI), Eastern Cooperative Oncology Group (ECOG) performance status, histories of autoimmune disease (AD), infection within 3 months before treatment, brain metastasis) collected grouped. Associations each patient factor time-to-treatment initiation (TTI) immune-related adverse events (irAEs) examined via cumulative incidence analyses Chi-squared tests, respectively. Log-rank tests Cox models used assess association overall survival (OS). Of 125 patients (median age:70 years (50–88), 68 (54.4 %) males), 9 (7.2 had Medicaid/uninsured, 44 (35.2 ECOG ≥ 2, 101 (80.8 CCI 3, 16 (12.8 ADs, 14 (11.2 infections, 26 (20.8 metastases. In diagnosed stage IV (N = 62), no difference TTI was found by factors. Fifty irAEs occurred 12 differences occurrence advanced-stage group 123), OS did not differ factors, except for race (p 0.045). Whites showed an inferior than non-Whites multivariable regression. (Hazards ratio 2.82 [1.01–7.87], p 0.047). Previously poorly represented subgroups shown have significant delays use, general tolerance, comparable outcomes. This adds practical evidence clinically and/or socio-demographically marginalized populations.

Language: Английский

---

TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology

Bioactive Materials, Journal Year: 2024, Volume and Issue: 45, P. 567 - 583

Published: Dec. 13, 2024

Language: Английский

---

Liquid Biopsy in non-small cell lung cancer: exosomes as a tool for the study of biomarkers.

Published: Feb. 27, 2024

Biopsy in non-small cell lung cancer: exosomes as

Language: Английский

---

Personalized Molecular Therapies for Advanced Non-Small Cell Lung Cancer: Overcoming Heterogeneity to Optimize Treatment Response and Clinical Outcomes

Published: Jan. 1, 2024

Lung cancer remains one of the deadliest cancers. Novel, paradigm shifting treatments including immunotherapy and targeted therapies have recently been developed to cull deadly effects lung cancer, but many challenges remain. There a significant unmet need accurately predict optimally select for patients who will respond immune checkpoint inhibitors (ICI) treatment. In Chapter 2 this dissertation, we investigated novel live single cell cytokine profiling lab-on-chip platform, IsoLight, using peripheral CD4+ CD8+ T-cells ICI biomarker development. A total 55,175 T-lymphocytes were analyzed in proof-of-concept study. We found that an increase overall polyfunctionality (PolyFx) polyfunctional strength index (PSI) T-cells, not after cycles correlated significantly with treatment response, better performance than PD-L1 TPS (p=0.082) alone. When combined TPS, response kappa coefficient 1.0 (p=0.003). Moreover, induction PSI (ΔPSI>5) strong trend long-term survival outcomes benefits (PFS; 3.9-fold; OS; 3-fold). 3 focuses on oncogene-addictive ALK-fusion NSCLC as our model precision therapy drug resistance. molecular genesis evolution rapid-onset drug-tolerant persistence, both genomics-matching lines, patient-derived (Ma-ALK001.S) line xenograft models. Together, identified tumoral autocrine TGFb2-PRC-2-EZH2/UTX-HOXB3 mediated signaling cascade key non-genetic epigenetic mechanism ALK-TKI persister cells, early between 8 hr 14 days. Importantly, EZH2/UTX could be leveraged therapeutic vulnerabilities persisters. Bulk RNA-sequencing scRNA-seq bioinformatics analysis Ma-ALK001.S PDC under alectinib stages transcriptomic reprogramming: Genesis (0, 3, hr), Early (3, 6, 9 days), Late stage (30, 60, 120 days). Pathway nominated crucial role cAMP-PKA upregulated states genesis, especially during - days post-alectinib plasticity reprogramming, associating dominance G2/M G0/G1 cycle arrest states. pharmacologic inhibition adenylyl cyclase activator forskolin, inhibitor KH7 provides promising preemptive approach persistence clinical improvement therapy. summary, strategies optimize ICI- therapy-treated NSCLCs.

Language: Английский

---

Efficacy and safety of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy in patients with stage IV NSCLC

JTO Clinical and Research Reports, Journal Year: 2024, Volume and Issue: 6(1), P. 100748 - 100748

Published: Oct. 19, 2024

Language: Английский

---

Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan

Targeted Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 28, 2024

Language: Английский

---